An Analysis of the Effectiveness of E-Commerce at United Parcel Service

This paper is an analysis of e-commerce at United Parcel Service (NYSE: UPS). The paper begins with a general overview of the company’s IT environment to establish awareness of the size and complexity of this corporation. The analysis includes a macro level breakdown of the technology infrastructure of UPS ranging from the amount of data centers the company has, to the amount of PCs currently in operation. The study also more closely analyzes the software and database structure of UPS. Furthermore, an analysis of the company’s E-commerce activities was conducted and includes an interview with Tom Creech, the North Florida District E-commerce manager at UPS. Finally, research was conducted to evaluate the emerging technologies that UPS will soon be implementing and should be employing in the future to support the business strategy and maintain its competitive edge

United Parcel Services IT Infrastructure: A Case Analysis

This analysis of the information technology infrastructure at United Parcel Service (UPS) begins with a general overview of the companys information technology (IT) environment to establish awareness of the size and complexity of this corporation. It includes a macro-level breakdown of the technology infrastructure of UPS ranging from the data centers to the PCs currently in operation. The study also more closely analyzes the software and database structure of UPS along with an analysis of the companys E-commerce activities. It includes an interview with Tom Creech, the North Florida District E-commerce manager at UPS. Finally, research was conducted to evaluate the emerging technologies that UPS is implementing and employing to support the business strategy and maintain its competitive edge

Design, development and prototyping of portable Potty as part of Petit en Suite Child’s Pop-up Privacy Room

Simple Creation Ltd had an idea of creating a portable potty that provided infant privacy whilst potty training her infant. Following a substantial amount of personal research they identified that nothing existing on the market to tackle this problem. The product design team at the University of Huddersfield met with Simple Creation team a number of times to design a new potty with the following objectives: • Optimise the present design: material, components, weight, functionality • Design for manufacture in injection moulding • Minimal manufacturing cost • Easy to clean • Easy to carry and store with adjustable height • Skin contact with the plastic bag is minima

Evidence-based selection of theories for designing behaviour change interventions : using methods based on theoretical construct domains to understand clinicians' blood transfusion behaviour

Peer reviewedPostprin

A cross-country comparison of intensive care physicians' beliefs about their transfusion behaviour : a qualitative study using the theoretical domains framework

Pub Med ID 22999460 PMCID: PMC3527303Peer reviewedPublisher PD

Mobile early detection and connected intervention to coproduce better care in severe mental illness

Current approaches to the management of severe mentalillness have four major limitations: 1) symptom reporting isintermittent and subject to problems with reliability; 2) serviceusers report feelings of disengagement from their careplanning; 3) late detection of symptoms delay interventionsand increase the risk of relapse; and 4) care systems are heldback by the costs of unscheduled hospital admissions thatcould have been avoided with earlier detection andintervention. The ClinTouch system was developed to close theloop between service users and health professionals.ClinTouch is an end-to-end secure platform, providing avalidated mobile assessment technology, a web interface toview symptom data and a clinical algorithm to detect risk ofrelapse. ClinTouch integrates high-resolution, continuouslongitudinal symptom data into mental health care servicesand presents it in a form that is easy to use for targeting carewhere it is needed. The architecture and methodology can beeasily extended to other clinical domains, where the paradigmof targeted clinical interventions, triggered by the earlydetection of decline, can improve health outcomes

Discovery of an Excess of Halpha Emitters around 4C 23.56 at z=2.48

We report the discovery of a significant excess of candidate Halpha emitters (HAEs) in the field of the radio galaxy 4C 23.56 at z=2.483. Using the MOIRCS near-infrared imager on the Subaru Telescope we found 11 candidate emission-line galaxies to a flux limit of ~7.5 10^-17 erg s-1 cm-2, which is about 5 times excess from the expected field counts with ~3-sigma significance. Three of these are spectroscopically confirmed as redshifted Halpha at z=2.49. The distribution of candidate emitters on the sky is tightly confined to a 1.2-Mpc-radius area at z=2.49, locating 4C 23.56 at the western edge of the distribution. Analysis of the deep Spitzer MIPS 24 mu m imaging shows that there is also an excess of faint MIPS sources. All but two of the 11 HAEs are also found in the MIPS data. The inferred star-formation rate (SFR) of the HAEs based on the extinction-corrected Halpha luminosity (median SFR >~100 M_solar yr-1) is similar to those of HAEs in random fields at z~2. On the other hand, the MIPS-based SFR for the HAEs is on average 3.6 times larger, suggesting the existence of the star-formation significanly obscured by dust. The comparison of the Halpha-based star-formation activities of the HAEs in the 4C 23.56 field to those in another proto-cluster around PKS 1138-262 at z=2.16 reveals that the latter tend to have fainter Halpha emission despite similar K-band magnitudes. This suggests that star-formation may be suppressed in the PKS 1138-262 protocluster relative to the 4C 23.56 protocluster. This difference among the HAEs in the two proto-clusters at z > 2 may imply that some massive cluster galaxies are just forming at these epochs with some variation among clusters.Comment: 29 pages, 13 figures, to be published in PASJ Subaru Special Issue (2011 Mar.

Effect of vaccination on transmission of SARS-CoV-2

No abstract available

V2494 cyg: A unique FU ori type object in the cygnus OB7 complex

A photometric and spectral study of the variable star V2494 Cyg in the L 1003 dark cloud is presented. The brightness of the star, formerly known as HH 381 IRS, increased by 2.5 mag in R (probably in the 1980s) and since then has remained nearly constant. Since the brightness increase, V2494 Cyg has illuminated a bipolar cometary nebula. The stellar spectrum has several features typical of the FU Ori (FUor) type, plus it exhibits very strong Ha and forbidden emissionlines with high-velocity components. These emission lines originate in the Herbig-Haro (HH) jet near the star. The kinematic age of the jet is consistent with it forming at the time of the outburst leading to the luminosity increase. V2494 Cyg also produces a rather extended outflow; it is the first known FUor with both an observed outburst and a parsec-sized HH flow. The nebula, illuminated by V2494 Cyg, possesses similar morphological and spectral characteristics to Hubble's variable nebula (R Monocerotis/NGC 2261). © 2013 The Authors Published by Oxford University Press on behalf of the Royal Astronomical Society

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England : test negative case-control study

Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital, and deaths. Design Test negative case-control study. Setting Community testing for covid-19 in England. Participants 156 930 adults aged 70 years and older who reported symptoms of covid-19 between 8 December 2020 and 19 February 2021 and were successfully linked to vaccination data in the National Immunisation Management System. Interventions Vaccination with BNT162b2 or ChAdOx1-S. Main outcome measures Primary outcomes were polymerase chain reaction confirmed symptomatic SARS-CoV-2 infections, admissions to hospital for covid-19, and deaths with covid-19. Results Participants aged 80 years and older vaccinated with BNT162b2 before 4 January 2021 had a higher odds of testing positive for covid-19 in the first nine days after vaccination (odds ratio up to 1.48, 95% confidence interval 1.23 to 1.77), indicating that those initially targeted had a higher underlying risk of infection. Vaccine effectiveness was therefore compared with the baseline post-vaccination period. Vaccine effects were noted 10 to 13 days after vaccination, reaching a vaccine effectiveness of 70% (95% confidence interval 59% to 78%), then plateauing. From 14 days after the second dose a vaccination effectiveness of 89% (85% to 93%) was found compared with the increased baseline risk. Participants aged 70 years and older vaccinated from 4 January (when ChAdOx1-S delivery commenced) had a similar underlying risk of covid-19 to unvaccinated individuals. With BNT162b2, vaccine effectiveness reached 61% (51% to 69%) from 28 to 34 days after vaccination, then plateaued. With ChAdOx1-S, effects were seen from 14 to 20 days after vaccination, reaching an effectiveness of 60% (41% to 73%) from 28 to 34 days, increasing to 73% (27% to 90%) from day 35 onwards. On top of the protection against symptomatic disease, a further 43% (33% to 52%) reduced risk of emergency hospital admission and 51% (37% to 62%) reduced risk of death was observed in those who had received one dose of BNT162b2. Participants who had received one dose of ChAdOx1-S had a further 37% (3% to 59%) reduced risk of emergency hospital admission. Follow-up was insufficient to assess the effect of ChAdOx1-S on mortality. Combined with the effect against symptomatic disease, a single dose of either vaccine was about 80% effective at preventing admission to hospital with covid-19 and a single dose of BNT162b2 was 85% effective at preventing death with covid-19. Conclusion Vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic covid-19 in older adults, and with further protection against severe disease. Both vaccines showed similar effects. Protection was maintained for the duration of follow-up (>6 weeks). A second dose of BNT162b2 was associated with further protection against symptomatic disease. A clear effect of the vaccines against the B.1.1.7 variant was found